HOUSTON--(BUSINESS WIRE)--Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that three abstracts on the Company’s lead product candidate, BPX-501, an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation, were accepted for poster presentation at the 57th American Society of Hematology (ASH) Annual Meeting.
Help employers find you! Check out all the jobs and post your resume.
